Adults with diabetes and CKD, diuretics D ACEi or ARB versus placebo, standard of care, or no treatment Table S28. Adults with diabetes and CKD, aliskiren versus ACEi or ARB. Table S29. Adults with type 2 diabetes and CKD, aliskiren D ACEi or ARB versus placebo D ACEi or ARB Table S30. Adults with diabetes and CKD, calcium channel blocker versus ACEi or ARB Table S31. Adults with CKD, dual RASi therapy versus single RASi therapy Table S32. Network meta-analysis of adults with CKD, dual RASi therapy versus single RASi therapy Table S33. Kidney transplant recipients, calcium channel blockers versus placebo or no treatment Table S34. Kidney transplant recipients, ARB versus placebo or no treatment Table S35. Kidney transplant recipients, ACEi versus placebo, no treatment, or non-antihypertensive treatment Table S36. Kidney transplant recipients, alpha-blocker versus placebo or no treatment Table S37. Kidney transplant recipients, beta-blocker versus placebo or no treatment Table S38. Kidney transplant recipients, mineralocorticoid receptor antagonists versus placebo Table S39. Kidney transplant recipients, ACEi or ARB versus placebo, no treatment, or standard of care Table S40. Children with CKD, intensi ed blood pressure control (MAP <50th percentile) versus conventional blood pressure control (MAP 50th 99th percentile) Appendix D. Data supplement - Additional SoF tables developed as part of the evidence review Table S41. Correlation of blood pressure measurement techniques in patients with CKD Table S42. Accuracy of blood pressure measurement techniques in the general population Table S43. Systematic reviews of approaches to blood pressure measurement in the general population and associations with clinical outcomes Table S44. Systematic reviews of economic evaluations of differing approaches to BP measurement in the general population Table S45. Adults with diabetes and CKD and habitual low-salt intake, higher dietary salt intake (through NaCl supplement) versus regular-salt intake Table S46. 